Report Overview:
Animal-derived dural patches are bioengineered surgical implants primarily sourced from bovine or porcine collagen tissues. These biomaterials serve as critical components in neurosurgical procedures, specifically designed to repair and regenerate the dura mater - the tough outermost membrane surrounding the brain and spinal cord. Their popularity stems from excellent tissue compatibility and structural properties that closely mimic human dura, facilitating natural healing processes while minimizing adverse reactions.
The market expansion is driven by rising neurosurgical procedure volumes, technological advancements in biomaterials, and increasing acceptance of animal-derived medical products. However, manufacturers continue to address challenges including ethical concerns and potential disease transmission risks through rigorous quality control measures and product innovation. Leading companies are investing in research to enhance material properties while maintaining compliance with stringent regulatory standards across different geographical markets.
Market Value:
Global animal derived dural patch market was valued at USD 551 million in 2023 and is projected to reach USD 853 million by 2030, exhibiting a CAGR of 6.5% during the forecast period.
CAGR of 6.5% (2024 – 2032)
By Applications:
Orthopedic surgery
Cardiovascular surgery
Plastic and reconstructive surgery
By Types:
• Bovine-derived materials
• Porcine-derived materials
• Equine-derived materials
Key players include:
• Integra LifeSciences (U.S.)
• Tianxinfu Medical Appliance (China)
• Medtronic (Ireland)
• B. Braun (Germany)
• Baxter International (U.S.)
• Zhenghai Bio-Tech (China)
• Guanhao Biotech (China)
• Cook Medical (U.S.)
